RxDoctor Payments Data

Sagar Chokshi, MD

Pain Medicine · Houston, TXNPI 1871855163

Payments from drug & device makers

$4,626in general payments, 2019–2025

Across 169 payments — averaging $27.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SPR Therapeutics, Inc$1K
  • Boston Scientific$632
  • Medtronic$517
  • Arbor Pharmaceuticals, Inc.$258
  • Nevro Corp.$221
  • Amgen$204
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$79717%
  • Food & beverage$3,82983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,626 in reported general payments places this provider in the 55th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$364,156
Medicare patients
495
Services billed
10,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl11$6,842
ButransBuprenorphine11$5,484
Gabapentin438$4,605
Pregabalin123$1,882
Methocarbamol116$1,583
Tramadol Hcl248$1,417
Tizanidine Hcl53$1,199
Celecoxib67$1,190
Lidocaine12$1,143
Butorphanol Tartrate13$591
Acetaminophen-CodeineAcetaminophen With Codeine55$563
Duloxetine Hcl48$527
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$410
Nortriptyline Hcl34$372
Cyclobenzaprine Hcl52$337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er$11$6,84211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →